CASI Pharmaceuticals Faces Nasdaq Compliance Challenge

CASI Pharmaceuticals ( (CASI) ) has provided an announcement.

On May 7, 2025, CASI Pharmaceuticals announced that it received a deficiency notice from Nasdaq due to non-compliance with the minimum Market Value of Listed Securities requirement of $35 million. The company has until November 3, 2025, to regain compliance or face potential delisting. This notice does not immediately affect the company’s Nasdaq listing, and CASI plans to take actions to meet the requirements, although there is no assurance of success.

Spark’s Take on CASI Stock

According to Spark, TipRanks’ AI Analyst, CASI is a Neutral.

CASI Pharmaceuticals faces substantial financial difficulties, with declining revenues and increasing losses, reflected in a low financial performance score. The technical analysis indicates a bearish trend, and the valuation is unattractive due to negative earnings and lack of dividends. These factors contribute to a low overall stock score, highlighting the need for significant improvements in operational efficiency and revenue growth.

To see Spark’s full report on CASI stock, click here.

More about CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and globally. The company specializes in hematology oncology therapeutics, organ transplant rejection, autoimmune diseases, and other unmet medical needs. CASI aims to become a leader in the Greater China market by leveraging its regulatory and commercial competencies.

Average Trading Volume: 9,780

Technical Sentiment Signal: Sell

Current Market Cap: $27.89M

See more insights into CASI stock on TipRanks’ Stock Analysis page.